{
    "clinical_study": {
        "@rank": "117788", 
        "arm_group": {
            "arm_group_label": "GS010", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability profile of ascending\n      doses of GS010 in Leber Hereditary Optic Neuropathy (LHON) patients."
        }, 
        "brief_title": "Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients", 
        "condition": "Leber Hereditary Optic Neuropathy", 
        "condition_browse": {
            "mesh_term": [
                "Optic Nerve Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes", 
                "Optic Atrophy, Hereditary, Leber"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Documented diagnosis of LHON based on a genetic test confirming the presence of the\n        G11778A mutation in the mitochondrial ND4\n\n        Age 18 years old or older at the time of study entry (informed consent signature)\n\n        Visual acuity \u2264 1/10 of the less functional eye\n\n        Exclusion Criteria:\n\n        Any known allergy or hypersensibility to one of the product used during the trial\n\n        Contraindication to IVT surgery (anaemia Hb <8g/dl, severe cardiovascular disease, severe\n        coagulopathy\u2026)\n\n        Disorder of the ocular humors and of the internal retina involving visual disability\n\n        Glaucoma\n\n        Presence of other pathology whose symptoms or associated treatments might affect the\n        retina or the optic nerve Vascular retinal occlusion\n\n        Narrow angle contra-indicating pupillary dilation\n\n        Other cause of optic neuropathy (inflammatory conditions or exposure to toxins...)\n\n        Patients presenting known mutation of other genes implicated in pathological retinal\n        conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064569", 
            "org_study_id": "GS-LHON/CLIN/01"
        }, 
        "intervention": {
            "arm_group_label": "GS010", 
            "intervention_name": "GS010", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 14, 2014", 
        "link": {
            "description": "Sponsor web site", 
            "url": "http://www.gensight-biologics.com/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75012"
                }, 
                "name": "CIC du CHNO DES QUINZE-VINGTS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene", 
        "overall_contact": {
            "email": "sfitoussi@gensight-biologics.com", 
            "last_name": "Serge Fitoussi, MD", 
            "phone": "+33 (6) 65 75 78 41"
        }, 
        "overall_official": {
            "affiliation": "CIC CHNO DES QUINZE VINGTS", 
            "last_name": "CATHERINE VIGNAL, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of local and general adverse events and Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GenSight Biologics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GenSight Biologics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}